This clinical trial is focused on studying a type of cancer called Multiple Myeloma, which affects the blood and bone marrow. The study is specifically for patients whose cancer has returned or has not responded to previous treatments, known as Relapsed or Refractory Multiple Myeloma. The main treatment being tested in this study is a medication called Alnuctamab, which is being compared to standard treatments that are currently used for this condition. The goal of the study is to determine if Alnuctamab can help patients live longer without their cancer worsening.
Participants in the study will receive either Alnuctamab or one of the standard treatments. The study will monitor how long it takes for the cancer to progress or for the patient to pass away, which is referred to as “progression-free survival.” Researchers will also look at the overall survival of participants, which means how long they live in total. Additionally, the study will assess how well the cancer responds to the treatment, the duration of the response, and the time it takes for patients to start a new treatment. The safety of Alnuctamab and any side effects experienced by participants will also be closely monitored.
The study aims to provide valuable information on whether Alnuctamab is a safe and effective treatment option for people with Multiple Myeloma. The trial is expected to continue until 2031, with recruitment of participants starting in 2024. This research could potentially lead to new treatment options for patients with this challenging condition.
Austria 
Belgium 
Czechia 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Norway 
Portugal 
Romania 
Spain 
Sweden 